Phaseline

Targets › CD3

CD3: drug programs, companies and trials

24 programs from 19 companies in 31 trials: 29 Phase 1, 2 Phase 2; Oncology, Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: the race on CD3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2825 Injection
CD3/CD20 bispecific antibody
CD3, CD20Phase 2Diffuse Large Cell B-lymphomaFeb 2028
Institute of Hematology & Blood Diseases Hospital, ChinaQLS4131
BCMA/GPRC5D/CD3 trispecific antibody
BCMA, GPRC5D, CD3Phase 2Primary Plasma Cell LeukemiaDec 2029
MacroGenicsMGD024
CD123 x CD3 bispecific DART molecule
CD123, CD3Phase 1Leukemia, Acute MyeloidNov 2026
Lakefront Biotherapeutics WestOM336
Bispecific antibody targeting BCMA and CD3
BCMA, CD3Phase 1AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens DiseaseDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQB2825 injection
CD20/CD3 bispecific antibody
CD20, CD3Phase 1Diffuse Large B Cell LymphomaDec 2026
Excyte BiopharmaYK012
Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate
CD19, CD3Phase 1Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin LymphomaDec 2026
Kali TherapeuticsKT501
Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells
CD19, BCMA, CD3Phase 1Rheumatoid Arthritis (RA)Feb 2027
Johnson & Johnson (Janssen)JNJ-80948543
T-cell redirecting trispecific antibody against CD79b, CD20, and CD3
CD79B, CD20, CD3Phase 1Lymphoma, Non-HodgkinMar 2027
Memorial Sloan Kettering Cancer CenterAntithymocyte globulin (ATG)
Polyclonal antibody targeting T lymphocytes; immunosuppressant
CTLA4, CD2, CD3, CD4, CD8Phase 1Myeloid Diseases; Hematologic MalignanciesMay 2027
Vironexis BiotherapeuticsVNX-101
Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager
CD3, CD19Phase 1B-cell Acute Lymphoblastic LeukemiaJun 2027
OncoC4ONC-783
Bispecific antibody targeting CD24 and CD3
CD24, CD3Phase 1Advanced Solid TumorAug 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2934
Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager)
CD3, BCMAPhase 1Multiple MyelomaOct 2027
Paul SzabolcsCD3/CD19 negative hematopoietic stem cells
Negatively selected hematopoietic stem cells depleted of CD3+ and CD19+ cells
CD3, CD19Phase 1Idiopathic Pulmonary FibrosisDec 2027
University of VirginiaEGFR FPBMC
CD3 x EGFR bispecific antibody-armed fresh peripheral blood mononuclear cells
CD3, EGFRPhase 1Pancreas CancerDec 2027
Kali TherapeuticsKT502
Monoclonal antibody targeting CD19 and CD3 for B cell depletion
CD19, CD3Phase 1Rheumatoid Arthritis (RA)Dec 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2029 for injection
bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill
GPRC5D, CD3Phase 1Multiple MyelomaMar 2028
Shanghai EpimAb BiotherapeuticsEMB-07
Bispecific antibody targeting CD3 and ROR1
CD3, ROR1Phase 1Combination TherapyJun 2028
Antengene BiologicsATG-201
Bispecific T-cell engager (TCE) binding CD3 and CD19
CD3, CD19Phase 1Systemic Lupus ErythematosusDec 2028
AstraZenecaAZD6621
T cell-engaging antibody targeting STEAP2, CD3, and CD8
STEAP2, CD3, CD8Phase 1Prostate CancerMar 2029
Cartography BiosciencesCBI-1214
Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells
LY6G6D, CD3Phase 1Colorectal CancerApr 2029
Shanghai EpimAb BiotherapeuticsEMB-15
Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager
ALPP, ALPG, CD3Phase 1Locally Advanced or Metastatic Solid TumorsMay 2029
University of VirginiaHER2 FPBMC
Anti-CD3 x anti-HER2 bispecific antibody armed fresh peripheral blood mononuclear cells
HER2, CD3Phase 1Breast CancerOct 2029
Diane GeorgeCliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device)
CD34+ cell selection device for T-cell depletion from peripheral blood stem cell transplan
CD34, CD3Phase 1Bone Marrow Failure SyndromeFeb 2030
Vironexis BiotherapeuticsVNX-202
Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager
CD3, ERBB2Phase 1HER2 Expressing Solid TumorsSep 2033

Conditions

Lymphoma, Non-Hodgkin (3) B-cell Acute Lymphoblastic Leukemia (2) Multiple Myeloma (2) Rheumatoid Arthritis (RA) (2) Bone Marrow Failure Syndrome (1) Primary Membranous Nephropathy (1) Systemic Lupus Erythematosus (SLE) (1) Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (1) Advanced Solid Tumor (1) Breast Cancer (1) AIHA - Warm Autoimmune Hemolytic Anemia (1) Sjogrens Disease (1)

Modalities

small molecule (15), other (3), mixed (3), protein or peptide (2), antibody (1)

Companies

University of Virginia (2) Vironexis Biotherapeutics (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) Shanghai EpimAb Biotherapeutics (2) Kali Therapeutics (2) Johnson & Johnson (Janssen) (1) Diane George (1) Excyte Biopharma (1) OncoC4 (1) Lakefront Biotherapeutics West (1) Paul Szabolcs (1) Memorial Sloan Kettering Cancer Center (1) Institute of Hematology & Blood Diseases Hospital, China (1) Antengene Biologics (1) AstraZeneca (1) Chia Tai Tianqing Pharmaceutical Group (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Cartography Biosciences (1) MacroGenics (1)

Related targets

CD19 (6) BCMA (4) CD20 (3) CD8 (2) GPRC5D (2) CD79B (1) CD34 (1) CD24 (1) HER2 (1) CTLA4 (1) CD2 (1) CD4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.